|
1
|
Chen WQ, Li H, Sun KX, Zheng RS, Zhang SW,
Zeng HM, Zou XN, Gu XY and He J: Report of cancer incidence and
mortality in China, 2014. Zhonghua Zhong Liu Za Zhi. 40:5–13.
2018.(In Chinese). PubMed/NCBI
|
|
2
|
Li G, Chen X, Yu J and Liu H: Clinical
research status of laparoscopic gastric cancer surgery in China,
Japan and South Korea. Zhonghua Wei Chang Wai Ke Za Zhi.
21:126–131. 2018.(In Chinese). PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Q, Xu Z and Chen JF: Progress in the
drug treatment of gastric cancer. Oncol Progress. 12:22–28.
2014.
|
|
5
|
Sun J, Song Y, Wang Z, Chen X, Gao P, Xu
Y, Zhou B and Xu H: Clinical significance of palliative gastrectomy
on the survival of patients with incurable advanced gastric cancer:
A systematic review and meta-analysis. BMC Cancer. 13:5772013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sougioultzis S, Syrios J, Xynos ID,
Bovaretos N, Kosmas C, Sarantonis J, Dokou A, Tzivras D, Zografos
G, Felekouras E, et al: Palliative gastrectomy and other factors
affecting overall survival in stage IV gastric adenocarcinoma
patients receiving chemotherapy: A retrospective analysis. Eur J
Surg Oncol. 37:312–318. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Izuishi K and Mori H: Recent strategies
for treating stage IV gastric cancer: Roles of palliative
gastrectomy, chemotherapy, and radiotherapy. J Gastrointestin Liver
Dis. 25:87–94. 2016.PubMed/NCBI
|
|
8
|
Cunningham D, Allum WH, Stenning SP,
Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ,
Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus
surgery alone for resectable gastroesophageal cancer. N Engl J Med.
355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wilke H, Preusser P, Fink U, Gunzer U,
Meyer HJ, Meyer J, Siewert JR, Achterrath W, Lenaz L, Knipp H, et
al: Preoperative chemotherapy in locally advanced and nonresectable
gastric cancer: A phase II study with etoposide, doxorubicin, and
cisplatin. J Clin Oncol. 7:1318–1326. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zuo CH, Ouyang YZ, Tang M, Tang W, Lin JG
and Zhu HZ: Progress in comprehensive treatment of gastric cancer.
Chin J Oper Proc Gen Surg. 6:319–324. 2012.
|
|
11
|
Ott K, Lordick F, Blank S and Buchler M:
Gastric cancer: Surgery in 2011. Langenbecks Arch Surg.
396:743–758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Furberg AS, Veierod MB, Wilsgaard T,
Bernstein L and Thune I: Serum high-density lipoprotein
cholesterol, metabolic profile, and breast cancer risk. J Natl
Cancer Inst. 96:1152–1160. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Healy LA, Ryan AM, Carroll P, Ennis D,
Crowley V, Boyle T, Kennedy MJ, Connolly E and Reynolds JV:
Metabolic syndrome, central obesity and insulin resistance are
associated with adverse pathological features in postmenopausal
breast cancer. Clin Oncol (R Coll Radiol). 22:281–288. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mutoh M, Akasu T, Takahashi M, Niho N,
Yoshida T, Sugimura T and Wakabayashi K: Possible involvement of
hyperlipidemia in increasing risk of colorectal tumor development
in human familial adenomatous polyposis. Jpn J Clin Oncol.
36:166–171. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ychou M, Boige V, Pignon JP, Conroy T,
Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM,
Saint-Aubert B, et al: Perioperative chemotherapy compared with
surgery alone for resectable gastroesophageal adenocarcinoma: An
FNCLCC and FFCD multicenter phase III trial. J Clin Oncol.
29:1715–1721. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Furberg AS and Thune I: Metabolic
abnormalities (hypertension, hyperglycemia and overweight),
lifestyle (high energy intake and physical inactivity) and
endometrial cancer risk in a Norwegian cohort. Int J Cancer.
104:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Backshall A, Sharma R, Clarke SJ and Keun
HC: Pharmacometabonomic profiling as a predictor of toxicity in
patients with inoperable colorectal cancer treated with
capecitabine. Clin Cancer Res. 17:3019–3028. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stebbing J, Sharma A, North B, Athersuch
TJ, Zebrowski A, Pchejetski D, Coombes RC, Nicholson JK and Keun
HC: A metabolic phenotyping approach to understanding relationships
between metabolic syndrome and breast tumour responses to
chemotherapy. Ann Oncol. 23:860–866. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang D, Li W, Zou Q, Yin L, Du Y, Gu J and
Suo J: Serum metabolomic profiling of human gastric cancer and its
relationship with the prognosis. Oncotarget. 8:110000–110015.
2017.PubMed/NCBI
|
|
20
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen AP, Setser A, Anadkat MJ, Cotliar J,
Olsen EA, Garden BC and Lacouture ME: Grading dermatologic adverse
events of cancer treatments: The common terminology criteria for
adverse events version 4.0. J Am Acad Dermatol. 67:1025–1039. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Becker K, Mueller JD, Schulmacher C, Ott
K, Fink U, Busch R, Böttcher K, Siewert JR and Höfler H:
Histomorphology and grading of regression in gastric carcinoma
treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mandard AM, Dalibard F, Mandard JC, Marnay
J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G,
et al: Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mirza A, Naveed A, Hayes S, Formela L,
Welch I, West CM and Pritchard S: Assessment of histopathological
response in gastric and Gastro-oesophageal junction adenocarcinoma
following neoadjuvant chemotherapy: Which scoring system to use?
ISRN Pathol. 2012:1–8. 2012. View Article : Google Scholar
|
|
25
|
Ninomiya Y, Yanagisawa A, Kato Y, Kitagawa
T, Ishihara S and Nakajima T: Histological indications of a
favorable prognosis with far-advanced gastric carcinomas after
preoperative chemotherapy. J Cancer Res Clin Oncol. 125:699–706.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kinoshita J, Fushida S, Tsukada T, Oyama
K, Okamoto K, Makino I, Nakamura K, Miyashita T, Tajima H, Takamura
H, et al: Efficacy of conversion gastrectomy following docetaxel,
cisplatin, and S-1 therapy in potentially resectable stage IV
gastric cancer. Eur J Surg Oncol. 41:1354–1360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M,
Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi
M, et al: Conversion therapy for inoperable advanced gastric cancer
patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: A
multi-institutional retrospective study. Gastric Cancer.
20:517–526. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tsunematsu M, Takahashi N, Murakami K,
Misawa T, Akiba T and Yanaga K: Successful conversion surgery for
gastric cancer with multiple liver metastases treated after S-1
plus cisplatin combination chemotherapy: A case report. Surg Case
Rep. 3:952017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lasithiotakis K, Antoniou SA, Antoniou GA,
Kaklamanos I and Zoras O: Gastrectomy for stage IV gastric cancer.
A systematic review and meta-analysis. Anticancer Res.
34:2079–2085. 2014.PubMed/NCBI
|
|
32
|
Park SC and Chun HJ: Chemotherapy for
advanced gastric cancer: Review and update of current practices.
Gut Liver. 7:385–393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kawada K, Toda K and Sakai Y: Targeting
metabolic reprogramming in KRAS-driven cancers. Int J Clin Oncol.
22:651–659. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nitta H, Kelly BD, Allred C, Jewell S,
Banks P, Dennis E and Grogan TM: The assessment of HER2 status in
breast cancer: the past, the present, and the future. Pathol Int.
66:313–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsuoka T and Yashiro M: Recent advances
in the HER2 targeted therapy of gastric cancer. World J Clin Cases.
3:42–51. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu J, Chen Y, Zhang R, Song Y, Cao J, Bi
N, Wang J, He J, Bai J, Dong L, et al: Global and targeted
metabolomics of esophageal squamous cell carcinoma discovers
potential diagnostic and therapeutic biomarkers. Mol Cell
Proteomics. 12:1306–1318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Salway JG: Metabolism at a Glance. (3rd).
Wiley-Blackwell. (Oxford). p1282013.
|
|
38
|
Nishibeppu K, Komatsu S, Ichikawa D,
Kosuga T, Okamoto K, Arita T, Konishi H, Morimura R, Murayama Y,
Shiozaki A, et al: Long-term complete response of peritoneal
recurrence from advanced gastric cancer using CapeOx therapy
following radical gastrectomy. Gan To Kagaku Ryoho. 44:1173–1175.
2017.(In Japanese). PubMed/NCBI
|
|
39
|
Li T, Liang M, Yuan J, Guo X, Feng D, Li
T, Teng D, Peng Z, Wu X, Li Z, et al: Correlated analysis of 5
fluorouracil metabolic enzymes with tumor response after SOX
regimen neoadjuvant chemotherapy in advanced gastric cancer.
Zhonghua Yi Xue Za Zhi. 94:127–130. 2014.(In Chinese). PubMed/NCBI
|
|
40
|
Gray LR, Tompkins SC and Taylor EB:
Regulation of pyruvate metabolism and human disease. Cell Mol Life
Sci. 71:2577–2604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen X, Wang J, Yan X, Ren X, Wang F, Chen
X and Xu Y: Predictive value of GSTP1 Ile105Val polymorphism in
clinical outcomes of chemotherapy in gastric and colorectal
cancers: A systematic review and meta-analysis. Cancer Chemother
Pharmacol. 77:1285–1302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dobrzynska I, Szachowicz-Petelska B,
Sulkowski S and Figaszewski Z: Changes in electric charge and
phospholipids composition in human colorectal cancer cells. Mol
Cell Biochem. 276:113–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dueck DA, Chan M, Tran K, Wong JT, Jay FT,
Littman C, Stimpson R and Choy PC: The modulation of choline
phosphoglyceride metabolism in human colon cancer. Mol Cell
Biochem. 162:97–103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kurabe N, Hayasaka T, Ogawa M, Masaki N,
Ide Y, Waki M, Nakamura T, Kurachi K, Kahyo T, Shinmura K, et al:
Accumulated phosphatidylcholine (16:0/16:1) in human colorectal
cancer; possible involvement of LPCAT4. Cancer Sci. 104:1295–1302.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yamaguchi K, Yoshida K, Tanahashi T,
Takahashi T, Matsuhashi N, Tanaka Y, Tanabe K and Ohdan H: The
long-term survival of stage IV gastric cancer patients with
conversion therapy. Gastric Cancer. 21:315–323. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ajani JA, D'Amico TA, Almhanna K, Bentrem
DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, et
al: Gastric cancer, version 3.2016, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 14:1286–1312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
